|Bid||0.6000 x N/A|
|Ask||0.6200 x N/A|
|Day's range||0.6000 - 0.6050|
|52-week range||0.4200 - 1.3500|
|Beta (5Y monthly)||1.00|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||1.39|
EBR Systems, Inc. (ASX:EBR), the medical device company developing wireless cardiac pacing systems, is proud to announce that positive results from the first completely leadless cardiac resynchronization therapy (CRT) in the United States have been published in The Journal of American College of Cardiology (JACC).
EBR Systems, Inc. (ASX:EBR), the developer of the world's only wireless cardiac pacing device for heart failure, is pleased to announce it has been named as a nominee for the 2023 Medical Technology Association of Australia (MTAA) Kerrin Rennie award.
EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems, has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE® Cardiac Resynchronization Therapy (CRT) System.